Ç¥ÀûÄ¡·á¿¬±¸È¸ Ãá°è½ÉÆ÷Áö¾ö : 2019-03-23±³À°ÀÏÀÚ : 2019-03-23
±³À°Àå¼Ò : ±è´ëÁßÄÁº¥¼Ç¼¾ÅÍ4Ãþ ÄÁº¥¼ÇȦ3
±³À°ÁÖÁ¦ :
Ç¥ÀûÄ¡·á¿¬±¸È¸ Ãá°è½ÉÆ÷Áö¾öÁÖÃÖ±â°ü : ´ëÇÑÆó¾ÏÇÐȸ
½ÃÇà±â°ü(ÁöºÎ/°ú) : Ç¥ÀûÄ¡·á¿¬±¸È¸
´ã´çÀÚ : ½É¹Î°æ
¿¬¶ôó : 02-741-8540
À̸ÞÀÏ :
kalc@lungca.or.kr ±³À°Á¾·ù : ³»°ú, ¿Ü°ú, ÈäºÎ¿Ü°ú, ¿µ»óÀÇÇаú, ¹æ»ç¼±Á¾¾çÇаú, º´¸®°ú, ÇÙÀÇÇаú
Âü¼®¿¹»óÀοø : 120¸í
Èñ¸ÁÆòÁ¡ : 3Á¡
Áö¿ª :
±¤ÁÖ±¤¿ª½Ã±³À°½Ã°£ : 3 ½Ã°£ 20ºÐ
¼¼ºÎ¼ö°·á : 70,000¿ø
ºñ°í »çÀüµî·Ï ȸ¿ø: 50,000¿ø/ ºñȸ¿ø 60,000¿ø ÇöÀåµî·Ï ȸ¿ø: 60,000¿ø/ ºñȸ¿ø 70,000¿ø
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 03-23 ÄÁº¥¼ÇȦ3 13:00~13:20 Strategies for treatment ion in EGFR mutant NSCLC based on real world data À±¼ºÈÆ(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 03-23 ÄÁº¥¼ÇȦ3 13:20~13:40 Emerging blood based biomarkers of immune checkpoint inhibitor response ¹Úµ¿¿ø(ÇѾçÀÇ´ë)
Åä·Ð 03-23 ÄÁº¥¼ÇȦ3 13:40~13:50 ()
ÈÞ½Ä 03-23 ÄÁº¥¼ÇȦ3 13:50~14:10 ()
±³À°½Ã°£ 03-23 ÄÁº¥¼ÇȦ3 14:10~14:30 Immunotherapy in surgically resectable NSCLC Á¤Ä¡¿µ(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 03-23 ÄÁº¥¼ÇȦ3 14:30~14:50 Consolidation immunotherapy after chemoradiation for unresectable NSCLC ¹ÚÂù±Ç(°¡Å縯ÀÇ´ë)
±³À°½Ã°£ 03-23 ÄÁº¥¼ÇȦ3 14:50~15:10 EGFR-TKI-based vs. non-EGFR-TKI-based adjuvant therapy in resected NSCLC with EGFR mutations Á¤Àç¿í(Ãæ³²ÀÇ´ë)
Åä·Ð 03-23 ÄÁº¥¼ÇȦ3 15:10~15:25 ()
ÈÞ½Ä 03-23 ÄÁº¥¼ÇȦ3 15:25~15:45 ()
±³À°½Ã°£ 03-23 ÄÁº¥¼ÇȦ3 15:45~16:05 Innovative treatments for SCLC ¹Úö±Ô(Àü³²ÀÇ´ë)
±³À°½Ã°£ 03-23 ÄÁº¥¼ÇȦ3 16:05~16:25 Immune checkpoint inhibitors in challenging populations À̽ÂÇö(°æÈñÀÇ´ë)
±³À°½Ã°£ 03-23 ÄÁº¥¼ÇȦ3 16:25~16:45 The role of immunotherapy in EGFR mutant NSCLC ¼±Á¾¹«(¼º±Õ°üÀÇ´ë)
Åä·Ð 03-23 ÄÁº¥¼ÇȦ3 16:45~17:00 ()